Non-Hodgkin's lymphomas, version 4.2014 Journal Article

   


Authors: Zelenetz, A. D.; Gordon, L. I.; Wierda, W. G.; Abramson, J. S.; Advani, R. H.; Andreadis, C. B.; Bartlett, N.; Byrd, J. C.; Czuczman, M. S.; Fayad, L. E.; Fisher, R. I.; Glenn, M. J.; Harris, N. L.; Hoppe, R. T.; Horwitz, S. M.; Kelsey, C. R.; Kim, Y. H.; Krivacic, S.; LaCasce, A. S.; Nademanee, A.; Porcu, P.; Press, O.; Rabinovitch, R.; Reddy, N.; Reid, E.; Saad, A. A.; Sokol, L.; Swinnen, L. J.; Tsien, C.; Vose, J. M.; Yahalom, J.; Zafar, N.; Dwyer, M.; Sundar, H.
Article Title: Non-Hodgkin's lymphomas, version 4.2014
Abstract: Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 12
Issue: 9
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2014-09-01
Start Page: 1282
End Page: 1303
Language: English
PROVIDER: scopus
PUBMED: 25190696
PMCID: PMC4839265
DOI: 10.6004/jnccn.2014.0125
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84907289619&partnerID=40&md5=dacde2f5b9438af571b75063b951fc1d
Notes: Export Date: 3 November 2014 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Joachim Yahalom
    626 Yahalom
  2. Steven M Horwitz
    645 Horwitz
  3. Andrew D Zelenetz
    768 Zelenetz
Related MSK Work